Segall Bryant & Hamill’s Catalyst Pharmaceutical CPRX Stock Holding History

Segall Bryant & Hamill’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.43M	Sell	138,585 -5,335	-4%	-$127K	0.05%	350
2025 Q4	$3.36M	Buy	143,920 +63,452	+79%	+$1.41M	0.05%	365
2025 Q3	$1.59M	Sell	80,468 -376	-0.5%	-$7.73K	0.02%	460
2025 Q2	$1.75M	Sell	80,844 -11,092	-12%	-$262K	0.02%	455
2025 Q1	$2.23M	Buy	91,936 +11,582	+14%	+$261K	0.03%	412
2024 Q4	$1.68M	Buy	80,354 +39,721	+98%	+$853K	0.02%	461
2024 Q3	$808K	Buy	+40,633	New	+$753K	0.01%	524

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Segall Bryant & Hamill's CPRX Position: Q1 2026 in Review

Segall Bryant & Hamill reduced its Catalyst Pharmaceutical (CPRX) stake by 3.7% in Q1 2026, selling an estimated $127K and leaving 138,585 shares worth $3.43M. The position accounts for 0.05% of the portfolio, ranked #350.

Segall Bryant & Hamill first reported a position in CPRX in Q3 2024 and has held it in 7 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Segall Bryant & Hamill held 138,585 shares of Catalyst Pharmaceutical worth $3.43M as of Q1 2026.
Segall Bryant & Hamill sold 5,335 Catalyst Pharmaceutical shares in Q1 2026, an estimated $127K.
Catalyst Pharmaceutical made up 0.05% of Segall Bryant & Hamill's portfolio in Q1 2026, its #350 holding.
Segall Bryant & Hamill first reported a position in Catalyst Pharmaceutical in Q3 2024 and has held it in 7 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Segall Bryant & Hamill's 13F filing for Q1 2026, filed 15 May 2026.